Skip to main content

Table 6 Scenario-analyses*: discounted and undiscounted incremental lifetime cost- effectiveness ratios

From: Cost-effectiveness of enzyme replacement therapy for Fabry disease

  ICER based on years free of end-organ damage, in € ICER based QALYs, in €
  Discounted Undiscounted Discounted Undiscounted
Base case typical patient 3,318,239 6,560,885 3,282,252 6,065,529
1. start ERT at 40 years 3,662,891 12,996,662 2,158,245 7,637,076
2. lower QoL during the natural course - - 509,719 1,226,674
3. course of disease in patients with the classical phenotype only 3,274,869 6,280,356 3,015,385 5,575,064
4. ACE-ARB during natural course 293,213,929 566,675,324 11,559,105 21,223,686
5. No ERT in case of 2 complications 3,307,363 6,529,644 3,271,494 6,036,644
6. including indirect costs of production loss 3,320,374 6,568,971 3,284,265 6,073,006
  1. * Given a 1:1 male to female ratio.